Download PDF
Thromb Haemost 1977; 38(04): 0733-0741
DOI: 10.1055/s-0038-1651894
Original Article
Schattauer GmbH

Bibliography of Sol Sherry

Further Information

Publication History

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

 

 
    A.

  • Research Publications

  • 1 The Vitamin C. Requirement of Man. Estimated after Prolonged Studies of the Plasma Concentration and Daily Excretion of Vitamin Cin 3 Adults on Controlled Diets. Ralli E. P, Friedman G. J, Sherry S. J. clin. Invest 1939; 18: 705.
    CrossrefPubMedGoogle Scholar
  • 2 Recovery of Vitamin C from the Human Bladder. Sherry S, Friedman G. J. Proc. Soc. exp. Biol. (N.Y.) 1939; 42: 707.
    CrossrefPubMedGoogle Scholar
  • 3 Effect of Insulin on Plasmin Level and Excretion of Vitamin C. Ralli E. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1940; 43: 669.
    CrossrefPubMedGoogle Scholar
  • 4 The Mechanism of the Excretion of Vitamin C by the Dog Kidney. Sherry S, Friedman G. J, Paley K, Berkman J, Ralli E. P. Amer. J. Physiol 1940; 130: 276.
    PubMedGoogle Scholar
  • 5 The Mechanism of the Excretion of Vitamin C by the Human Kidney at Low and Normal Plasma Levels of Ascorbic Acid. Friedman G. J, Sherry S, Ralli E. P. J. Clin. Invest 1940; 19: 685.
    CrossrefPubMedGoogle Scholar
  • 6 Further Studies of the Effects of Insulin on Vitamin C Metabolism. Sherry S, Ralli E. P. J. clin. Invest 1948; 27: 217.
    CrossrefPubMedGoogle Scholar
  • 7 Presence and Significance of Desoxyribose Nucleoprotein in the Purulent Pleural Exudates of Patients. Sherry S, TiLLEtt W. S, Christensen L. R. Proc. Soc. exp. Biol. (N. Y.) 1948; 68: 179.
    CrossrefPubMedGoogle Scholar
  • 8 Streptococcal Desoxyribonuclease: Significance in Lysis of Purulent Exudates and Production by Strains of Hemolytic Streptococci. Tillet W. S, Sherry S, Christensen L. R. Proc. Soc. exp. Biol. (N. Y.) 1948; 68: 184.
    CrossrefPubMedGoogle Scholar
  • 9 The Effect in Patients of Streptococcal Fibrinolysin (Streptokinase) and Streptococcal Desoxyribonuclease on Fibrinous, Purulent and Sanguinous Pleural Exudations. Tillet W. S, Sherry S. J. clin. Invest 1949; 28: 173.
    CrossrefPubMedGoogle Scholar
  • 10 The Action of Streptococcal Desoxyribose Nuclease (Streptodornase) in vitro and Purulent Pleural Exudations of Patients. Sherry S, Johnson A, Tillett W. S. J. Clin. Invest 1949; 28: 1094.
    CrossrefPubMedGoogle Scholar
  • 11 Streptococcal Enzymatic Debridement. Tillett W. S, Sherry S, Christensen L. R, Johnson A, Hazlehurst G. Ann. Surg 1949; 131: 12.
    PubMedGoogle Scholar
  • 12 Ultraviolet Photography of Paper Chromatograms in the Study of Nucleic Acids. Goeller J. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1950; 74: 381.
    CrossrefPubMedGoogle Scholar
  • 13 The Use of Streptokinase-Streptodornase in the Treatment of Hemothorax. Sherry S, Tillett W. S, Read C. T. J. thorac. Surg 1950; 20: 393.
    PubMedGoogle Scholar
  • 14 The Extent of the Enzymatic Degradation Desoxyribonucleic Acid (DNA) in Purulent Exudates by Streptodornase. Sherry S, Goeller J. P. J. clin. Invest 1950; 29: 1588.
    CrossrefPubMedGoogle Scholar
  • 15 The Use of Streptokinase-Streptodornase in the Treatment of Post-Pneumonic Empyema. Tillett W. S, Sherry S, Read C. T. J. thorac. Surg 1951; 21: 275.
    PubMedGoogle Scholar
  • 16 The Use of Streptokinase-Streptodornase in the Treatment of Chronic Empyema. Tillett W. S, Sherry S, Read C. T. J. thorac. Surg 1951; 21: 275.
    PubMedGoogle Scholar
  • 17 The Low Potassium Syndrome Due to Defective Renal Tubular Mechanisms for Handling Potassium. Earle D. P, Sherry S, Eichna L. W, Conan Jr. N. Amer. J. Med 1951; 11: 283.
    CrossrefPubMedGoogle Scholar
  • 18 The Rationale of the Therapeutic Use of Streptokinase-Streptodornase in Amebic Abscess of the Liver. Sherry S, McCarty W. R, Tillett W. S. Arch. intern. Med 1951; 88: 752.
    CrossrefPubMedGoogle Scholar
  • 19 The Local Use of Streptokinase-Streptodornase in Chronic Refractory Areas of Suppuration with Draining Sinuses. Sherry S, Tillett W. S. Ann. Surg 1952; 135: 479.
    CrossrefPubMedGoogle Scholar
  • 20 Changes in Clot Retraction Time and Platelet Adhesiveness following Whole Body Irradiation. Savitsky J. P, Sherry S. Proc. Soc. exp. Biol. (N. Y.) 1954; 84: 587.
    PubMedGoogle Scholar
  • 21 “Collagenase” Activity of Cathepsins. Sherry S, Troll W, Rosenblum E. D. Proc. Soc. exp. Biol. (N.Y.) 1954; 87: 125.
    CrossrefPubMedGoogle Scholar
  • 22 The Action of Plasmin on Synthetic Substrates. Troll W, Sherry S, Wachman J. J. biol. Chem 1954; 208: 85.
    PubMedGoogle Scholar
  • 23 The Action of Thrombin on Synthetic Substrates. Sherry S, Troll W. J. biol. Chem 1954; 208: 95.
    PubMedGoogle Scholar
  • 24 The Fibrinolytic Activity of Streptokinase Activated Human Plasmin. Sherry S. J. clin. Invest 1954; 33: 1054.
    CrossrefPubMedGoogle Scholar
  • 25 The Enzymatic Dissolution of Experimental Intervascular Thrombi in the Dog by Trypsin, Chemotrypsin and Plasminogen Activators. Sherry S, Titchener A, Gottesman L, Wasserman P, Troll W. J. clin. Invest 1954; 33: 1303.
    CrossrefPubMedGoogle Scholar
  • 26 Assay of Plasma Prothrombin with a Synthetic Substrate. Glueck H. I, Sherry S, Troll W. Proc. Soc. exp. Biol. (N. Y.) 1954; 87: 646.
    CrossrefPubMedGoogle Scholar
  • 27 The Activation of Human Plasminogen by Streptokinase. Troll W, Sherry S. J. biol. Chem 1954; 213: 881.
    PubMedGoogle Scholar
  • 28 Prevention of Post-operative Adhesions in the Dog by Intravenous Injections of Plasminogen Activators. Sherry S, Callaway D, Freiberg R. Proc. Soc. exp. Biol. (N.Y.) 1955; 90: 1.
    CrossrefPubMedGoogle Scholar
  • 29 Serum Transaminase. Observations in a large group of patients. Chinsky M, Shmagronoff G, Sherry S. J. Lab. clin. Med 1956; 47: 108.
    PubMedGoogle Scholar
  • 30 Some Effects of Orinase in the Rat. Lang S, Sherry S. Metabolism 1956; 5: 733.
    PubMedGoogle Scholar
  • 31 Experience with Orinase in the Management of Adult Diabetes. Braverman A. E, Drey N. W, Sherry S. Metabolism 1956; 5: 911.
    PubMedGoogle Scholar
  • 32 Serum Transaminase. A Comparison of the Serum Oxalacetic and Pyruvic Transaminase. Chinsky M, Wolff R. J, Sherry S. Amer. J. med. Sci 1957; 233: 400.
    CrossrefPubMedGoogle Scholar
  • 33 The Use of Tolbutamide in the Management of Adult Diabetes. Sherry S, Zeffren J. L, Braverman A. E, Drey N. Ann. N. Y. Acad, of Sciences 1957; 71: 249.
    PubMedGoogle Scholar
  • 34 An Approach to Intravascular Fibrinolysis in Man. Sherry S, Fletcher A. P, ALKJaeRSiG N, Smyrniotis F. E. Trans. Ass. Amer. Phycns 1975; 70: 288.
    PubMedGoogle Scholar
  • 35 The Effects of Prolonged Tolbutamide Therapy on the Hepatic Function and Serum Cholesterol of Adult Diabetic Patients. Zeffren J. L, Sherry S. Metabolism 1957; 6: 504.
    PubMedGoogle Scholar
  • 36 The Activation of Human Plasminogen. 1. Spontaneous Activation in Glycerol. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1958; 233: 81.
    PubMedGoogle Scholar
  • 37 The Activation of Human Plasminogen. 2. A Kinetic Study of Activation with Trypsin, Urokinase and Streptokinase. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1958; 233: 86.
    PubMedGoogle Scholar
  • 38 Physicochemical Studies on Human Plasminogen (Profibrinolysin) and Plasmin (Fibrinolysin). Shulman S, Alkjaersig N, Sherry S. J. biol. Chem 1958; 233: 91.
    PubMedGoogle Scholar
  • 39 Clearance of Heterologous Protein from the Circulation of Normal and Immunized Man. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1958; 37: 1306.
    CrossrefPubMedGoogle Scholar
  • 40 The Treatment of Patients Suffering from Early Myocardial Infarction with Massive and Prolonged Streptokinase Therapy. Fletcher A. P, Alkjaersig N, Smyrniotis F. E, Sherry S. Trans. Ass. Amer. Phycns 1958; 71: 278.
    PubMedGoogle Scholar
  • 41 Epsilon-Aminocaproic Acid: An Inhibitor of Plasminogen Activation. Alkjaersig N, Fletcher A. P, Sherry S. J. biol. Chem 1959; 234: 832.
    PubMedGoogle Scholar
  • 42 Urokinase Excretion in Health and its Alterations in Certain Disease States. Smyrniotis F, Fletcher A. P, Alkjaersig N, Sherry S. Thrombosis et Diathesis Haemorrhagica 1959; 3: 257.
    PubMedGoogle Scholar
  • 43 Studies on Enhanced Fibrinolytic Activity in Man. Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. J. clin. Invest 1959; 38: 810.
    CrossrefPubMedGoogle Scholar
  • 44 The Fibrinolysin System: Some Physiological Considerations. Sherry S, Fletcher A. P, Alkjaersig N. Conn. Tissues, Thrombosis and Atherosclerosis. Edited by Page I. Academic Press; 1959: 1959.
    Google Scholar
  • 45 The Mechanism of Clot Dissolution by Plasmin. Alkjaersig N, Fletcher A. P, Sherry S. J. clin. Invest 1959; 38: 1086.
    CrossrefPubMedGoogle Scholar
  • 46 The Maintenance of a Sustained Thrombolytic State in Man., I. Induction and Effects. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1959; 38: 1096.
    CrossrefPubMedGoogle Scholar
  • 47 The Maintenance of a Sustained Thrombolytic State in Man. II. Clinical Observations on Patients with Myocardial Infarction and Other Thromboembolic Disorders. Fletcher A. P, Sherry S, Alkjaersig N, Smyrniotis F. E, Jick S. J. clin. Invest 1959; 33: 1111.
    PubMedGoogle Scholar
  • 48 Epsilon-Aminocaproic Acid, “A Potent Antifibrinolytic Agent”. Sherry S, Fletcher A. P, Alkjaersig N, Sawyer W. D. Trans. Ass. Amer. Phycns 1959; 72: 62.
    PubMedGoogle Scholar
  • 49 Studies on the Thrombolytic Activity of Human Plasma. Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1960; 39: 426.
    CrossrefPubMedGoogle Scholar
  • 50 Evaluation of Human Fibrinolysin (Actase). Fletcher A. P, Alkjaersig N, Sawyer W. D, Sherry S. J. Amer. med. Ass 1960; 172: 912.
    CrossrefPubMedGoogle Scholar
  • 51 Comparison of Fibrinolytic and Fibrinogenolytic Effects of Plasminogen Activators and Proteolytic Enzymes in Plasma. Sawyer W. D, Alkjaersig N, Fletcher A. P, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1960; 5: 149.
    PubMedGoogle Scholar
  • 52 The Assay of Thrombolytic (Fibrinolytic) Mixtures Intend for Therapeutic Use. Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1961; 57: 620.
    PubMedGoogle Scholar
  • 53 Impairment of Hemostasis in the Urinary Tract: The Role of Urokinase. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1961; 58: 34.
    PubMedGoogle Scholar
  • 54 The Use of Epsilon-Aminocapronic Acid, A Potent Inhibitor of Fibrinolytic Activity, in the Management of Postoperative Hematuria. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Urol. (Baltimore) 1961; 86: 829.
    CrossrefPubMedGoogle Scholar
  • 55 Plasma Amino Acid Chromatography with Ion Exchange Resin Loaded Paper: Assay of Epsilon Aminocaproic Acid (EACA). McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1962; 59: 1.
    PubMedGoogle Scholar
  • 56 The Absorption, Distribution and Excretion of Epsilon-Aminocaproic Acid (EACA) Following its Oral or Intravenous Administration to Man. McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1962; 59: 15.
    PubMedGoogle Scholar
  • 57 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. I. The Significance of Fibrinogen Proteolyses and Circulating Fibrinogen Breakdown Products. Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1962; 41: 896.
    CrossrefPubMedGoogle Scholar
  • 58 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. II. The Significance Mechanism and Consequences of Defective Fibrin Polymerization. Alkjaersig N, Fletcher A. P, Sherry S. J. clin. Invest 1962; 41: 917.
    CrossrefPubMedGoogle Scholar
  • 59 Pathogenesis of the Coagulation Defect Developing During Pathological Plasma Proteolytic (“Fibrinolytic”) States. III. Demonstration of Abnormal Clot Structure by Electron Microscopy. Bang N. U, Fletcher A. P, Alkjaersig N, Sherry S. J. clin. Invest 1962; 41: 935.
    CrossrefPubMedGoogle Scholar
  • 60 Influence of pH, Ionic Strength, Neutral Ions and Thrombin on Fibrin Polymerization. Latallo Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Amer. J. Physiol 1962; 202: 681.
    PubMedGoogle Scholar
  • 61 Inhibition of Fibrin Polymerization by Fibrinogen Proteolysis Products. Latello Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Amer. J. Physiol 1962; 202: 681.
    PubMedGoogle Scholar
  • 62 Altered Fibrinolytic Mechanism in Hepatic Cirrhosis and its Potential Clinical Significance. Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. Trans. Ass. Amer. Phycns 1963; 76: 280.
    PubMedGoogle Scholar
  • 63 Abnormal Plasminogen-Plasmin System Activity (“Fibrinolysis”) in Patients with Hepatic Cirrhosis: Its Cause and Consequences. Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. J. clin. Invest 1964; 43: 681.
    CrossrefPubMedGoogle Scholar
  • 64 Assay of Urokinase Preparations with the Synthetic Substrate, Acetyl-1-lysine Methyl Ester. Sherry S, Alkjaersig N, Fletcher A. P. J. Lab. clin. Med 1964; 64: 145.
    PubMedGoogle Scholar
  • 65 The Assay of Plasma Thrombolytic Activity Using Fluorescein Labeled Clots. Genton E, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1964; 64: 313.
    PubMedGoogle Scholar
  • 66 The Purification and Properties of Plasminogen Activator from Pig Heart. Bachmann F, Alkjaersig N, Fletcher A. P, Sherry S. Biochemistry 1964; 3: 1578.
    CrossrefPubMedGoogle Scholar
  • 67 The Development of Urokinase as a Thrombolytic Agent. Maintenance of a Sustained Thrombolytic State in Man by its Intravenous Infusion. Fletcher A. P, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. J. Lab. clin. Med 1965; 65: 713.
    PubMedGoogle Scholar
  • 68 The Assay of Urokinase Preparations for Contamination with Thromboplastic Moieties. Alkjaersig N, Fletcher A. P, Sherry S. J. Lab. clin. Med 1965; 65: 732.
    PubMedGoogle Scholar
  • 69 The Effect of Fibrin and Fibrinogen Proteolysis Products on Clot Physical Properties. Hirsh J, Fletcher A. P, Sherry S. Amer. J. Physiol 1965; 209: 415.
    PubMedGoogle Scholar
  • 70 Comparative Activity of Thrombin on Substituted Arginine and Lysine Esters. Sherry S, Alkjaersig N, Fletcher A. P. Amer. J. Physiol 1965; 209: 577.
    PubMedGoogle Scholar
  • 71 Activity of Plasmin and SK-Activator on Substituted Arginine and Lysine Esters. Sherry S, Alkjaersig N, Fletcher A. P. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 16: 19.
    PubMedGoogle Scholar
  • 72 Observations on the Spontaneous Arginine and Lysine Esterase Activity of Human Plasma, and their Relation to Hageman Factor. Sherry S, Alkjaersig N, Fletcher A. P. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; Supplement 20: 243.
    PubMedGoogle Scholar
  • 73 The Preparation and Properties of Human Fibrinogen of Relatively High Solubility. Mosesson M. W, Sherry S. Biochemistry 1966; 5: 2829.
    CrossrefPubMedGoogle Scholar
  • 74 The Proteolysis of Fibrinogen by Plasmin: The Identification of Thrombin Clottable Fibrinogen Derivatives which Polymerize Abnormally. Fletcher A. P, Alkjaersig N, Fisher S, Sherry S. J. Lab. clin. Med 1966; 68: 780.
    PubMedGoogle Scholar
  • 75 The Enzymatic Lysis of Plasma Clots: The Influence of Fibrin Stabilization on Lysis Rates. Gormsen J, Fletcher A. P, Alkjaersig N, Sherry S. Arch, of Biochem. and Biophys 1967; 120: 654.
    CrossrefPubMedGoogle Scholar
  • 76 Human Fibrinogen of Relatively High Solubility: Comparative Biophysical, Biochemical and Biological Studies with Fibrinogen of Lower Solubility. Mosesson M. W, Alkjaersig N, Sweet B, Sherry S. Biochemistry 1967; 6: 3279.
    CrossrefPubMedGoogle Scholar
  • 77 Immunoelectrophoretic Characterization of Plasma Fibrinogen Derivatives in Patients with Pathological Plasma Proteolysis. Fisher S, Fletcher A. P, Alkjaersig N, Sherry S. J. Lab. clin. Med 1967; 70: 903.
    PubMedGoogle Scholar
  • 78 Studies of a Chronic Intravascular Coagulation Syndrome associated with plasma Cryoprecipitate (“Cryofibrinogen”) preceeding the appearance of Primary Ovarian Carcinoma. Mosesson M. W, Colman R, Sherry S. New Engl. J. Med 1968; 278: 815.
    CrossrefPubMedGoogle Scholar
  • 79 The Effect of Urokinase Antiserum on Plasminogen Activators: Demonstration of Immunologic Dissimilarity between Plasma Plasminogen Activator and Urokinase. Kucinski C, Fletcher A. P, Sherry S. J. clin. Invest 1968; 47: 1238.
    CrossrefPubMedGoogle Scholar
  • 80 Observations on the Plasma Kallikreinogen-Kallikrein Enzyme System. Sherry S, Colman R. W. Trans. Ass. Amer. Phycns 1968; 81: 40.
    PubMedGoogle Scholar
  • 81 Studies on the Kallikreinogen-Kallikrein Enzyme System of Human. Plasma. I. Isolation and Purification of Plasma Kallikreins. Colman R. W, Mattler L, Sherry S. J. clin. Invest 1969; 48: 11.
    CrossrefPubMedGoogle Scholar
  • 82 Studies on the Kallikreinogen-Kallikrein Enzyme System of Human Plasma. II. Identification of the Kaolin Activated Arginine Esterase as Plasma Kallikrein. Colman R. W, Mattler L, Sherry S. J. clin. Invest 1969; 48: 23.
    CrossrefPubMedGoogle Scholar
  • 83 The Kallikreinogen-Kallikrein Enzyme System of Human Plasma. Assay of Compenents and Preliminary Observations in Disease States. Colman R. W, Mason J. W, Sherry S. Ann. intern. Med 1969; 71: 763.
    CrossrefPubMedGoogle Scholar
  • 84 Isolation and Characterization of Clottable Low Molecular Weight Fibrinogen Derived by Limited Plasmin Hydrolysis of Human Fraction I-4. Sherman L. A, Mosesson M. W, Sherry S. Biochemistry 1969; 8: 1515.
    CrossrefPubMedGoogle Scholar
  • 85 In Vivo Transformation between Fibrinogen of Varying Ethanol Solubilities: A First Step in Fibrinogen Catabolism. Sherman L. A, Fletcher A. P, Sherry S. J. Lab. clin. Med 1969; 73: 574.
    PubMedGoogle Scholar
  • 86 The Purification of Fibrinogen Degradation Products by Pevikon Block Electrophoresis. Marder V. J, James H. L, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1969; 22: 234.
    PubMedGoogle Scholar
  • 87 The Urokinase-Pulmonary Embolism Trial. Phase I. Results. Urokinase-Pulmonary Embolism Trial Study Group. J. Amer. med. Ass 1970; 214: 2163.
    CrossrefPubMedGoogle Scholar
  • 88 Detection of Serum Fibrinogen and Fibrin Degradation Products. Comparison of Six Techniques using Purified Products and Application in Clinical Studies. Marder V. J, Matchett M. O, Sherry S. Amer. J. Med 1971; 51: 71.
    CrossrefPubMedGoogle Scholar
  • 89 Urokinase-Streptkokinase Pulmonary Embolism Trial. Phase II Results. A National Cooperative Trial. J. Amer. med. Ass 1974; 229: 1606.
    CrossrefPubMedGoogle Scholar
  • 90 Platelet Coagulant Activities and Venous Thrombosis After Hip Surgery. Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E, Sherry S. Trans. Ass. Amer. Phycns 1974; 89: 140-149.
    PubMedGoogle Scholar
  • 91 Effect of Plasmic Degradation Products of Fibrinogen on the Radioimmunoassay of Human Fibrinopeptide A. Budzynski A. Z, Marder V. J, Sherry S. Blood 1975; 45: 757-768.
    PubMedGoogle Scholar
  • 92 The Relationship of Platelet Coagulant Activities to Venous Thrombosis Following Hip Surgery. Walsh P. N, Rogers P. H, Marder V. J, Gagnatelli G, Escovitz E. S, Sherry S. Brit. J. Haemat 32: 421-436 1976;
    CrossrefPubMedGoogle Scholar
      • D.

    • Chapter and Articles in Books and Monographs

    • 1 Dynamics of Thrombosis. Sherry S. In Cerebral Vascular Diseases. Trans. Third Conf. Ed. Millikan C. H, Siekert R. G, Whisnant J. P. Grune & Stratton; N.Y.: 1961: 60.
      Google Scholar
    • 2 Rationale Limitations of the Use of Thrombolytic (Fibrinolytic) Agents in the Treatment of Thromboembolic Disease. Sherry S, Fletcher A. P, Alkjaersig N. Progress in Hematology. Edited by Tocantins L. M. Vol. III. Grune & Stratton; N.Y.: 1962: 244.
      Google Scholar
    • 3 Sections of Pulmonary Embolism and Infarction; Fat Embolism; and Pulmonary Hemorrhage. Sherry S. In Cecil and Loeb’s Textbook of Medicine. 11th Edition.. W. B. Saunders Company; Philadelphia: 1963: 560-568.
      Google Scholar
    • 4 Assays for Fibrinolytic Enzymes Based on the Use of Synthetic Substrates. Sherry S, Alkjaersig N, Fletcher A. P. in Blood Coagulation, Hemorrhage and Thrombosis. Methods of Study. Ed. Tocantins L. M, Kazal L. A. Grune & Stratton; N.Y.: 1964: 277.
      Google Scholar
    • 5 The “Ideal” Anticoagulant Drug. Sherry S. in Cardiovascular Drug Therapy (Hahnemann Symposium). Likoff E. W, Moyer J. H. Grune & Stratton; N. Y.; 1965. Chapter 37 235-239.
      Google Scholar
    • 6 Fibrinolytic Therapie: Current and Future Clinical Status. Sherry S. in Cardiovascular Drug Therapy (Hahnemann Symposium). Ed. Likoff W, Moyer J. H. Grune & Stratton; N. Y.: 1965. Chapter 38 261-265.
      Google Scholar
    • 7 Sections on Pulmonary Embolism and Infarction; Fat Embolism; Pulmonary Hemorrhage; and Fibrinolysis and Fibrinolytic Disorders. Sherry S. In: Cecil and Loeb’s Textbook of Medidne. 12th Edition.. W. B. Saunders Company; Philadelphia: 1967: 534-541 1136–1138.
      Google Scholar
    • 8 Thrombolytic Therapy in Acute Myocardial Infarction. Fletcher A. P, Sherry S. in Symposium on Coronary Heart Disease. 95 Ed. Blumgart H. L. American Heart Association Monograph No. 2 Am. Heart Assoc.; N. Y.: 1968
      Google Scholar
    • 9 Fibrinolysis and Thrombosis. Sherry S. In Thrombosis. Ed. Sherry S, Genton E, Brinkhous K. M, Stengle J. M. National Academy of Sciences; Washington, D.C.: 1969: 585-608.
      Google Scholar
    • 10 Section on Thromboembolic Diseases. Sherry S. In Cecil-Loeb’s Textbook of Medicine, 13th Edition. Ed. Beeson P. B, McDermott W. W. B. Saunders Co.; Philadelphia: 1971: 1040-1050.
      Google Scholar
    • 11 Mechanisms of Fibrinolysis. Sherry S. In Hematology. Ed. Williams W. J, Beutler E, Erslev A. J, Rundles R. W. Blakiston Division, McGraw-Hill Book Co.; 1972. Chapter 134 1105-1114.
      Google Scholar
    • 12 Fibrinolysis. Marder V, Sherry S. In Pathophysiology–Altered Regulatory Mechanisms. Ed. Frohlich E. J. B. Lippincott Co.; Philadelphia: 1972. Chapter 26 547-564 2nd Edition. in press.
      Google Scholar
    • 13 Priorities in Cardiovascular Research: Prevention of Coronary Artery Thrombosis. Sherry S. In Changing Concepts in Cardiovascular Disease. Russek E. H. I, Zohmann B. L. Williams & Wilkins; Baltimore: 1972: 300-306.
      Google Scholar
    • 14 Thrombolysis for Acute Myocardial Infarction. Sherry S. In Atherosclerosis and Coronary Heart Disease. Ed. Likoff W, Segal B. L, Insull W, Moyer J. H. Grune & Stratton; N. Y.: 1972: 426-430.
      Google Scholar
    • 15 Is Thrombolytic Therapy Justified. Sherry S. In Thromboembolism: Diagnosis and Treatment. Ed. Kakkar V. V, Jouhar A. J. Churchill Livingstone; Edinburgh and London: 1972: 144-153.
      Google Scholar
    • 16 Anticoagulants, Platelet Aggregation in Inhibitors and Fibrinolysis. Sherry S. In: Paul D. White Symposium: Major Advances in Cardiovascular Therapy. Ed. Russek H. I, Zohman B. L. Williams & Wilkins; Baltimore: In Press.
      Google Scholar
    • 17 Current Developments in Thrombolytic Therapy. Sherry S. In Present Status of Thrombosis. Its Pathophysiology, Diagnosis and Treatment. Ed.: Losito R. F. K. Schattauer Verlag; Stuttgart, New York: 1973: 201-210.
      Google Scholar
    • 18 Current Status of Urokinase Therapy. Sherry S. In Pulmonary Thromboembolism. Ed.: Moser K. M, Stein M. Yearbook Publishers, Inc.; 1973: 280-288.
      Google Scholar
    • 19 Detection of Thrombi. Sherry S. In Diagnostic Nuclear Cardiology. Ed. Patt P, Strauss H. W, James A. E. C. V. Mosby; St. Louis.:
      Google Scholar
    • 20 Thrombo-embolic Diseases. Sherry S. In: Cecil-Loebs Textbook of Medicine. 14th Edition.. Beeson P. B, McDermott W. Eds. W. B. Saunders, Co.; Phila.: 1975: 910-921.
      Google Scholar
    • 21 Fibrinolysis. Marder V. J, Sherry S. In: Pathophysiology-altered Regulatory Mechanisms. 2nd Edition.. Friohlich E. Ed. J. B. Lippincott; Cot., Phila.: (In press).
      Google Scholar
    • 22 Pulmonary Embolism and Infarction. Sherry S. In: “Cardiac Emergency Care”. Chung E. K. Ed. Lea and Febinger; Phila.: 1975: 17-33.
      Google Scholar
    • 23 Present Status of Antithrombotic Therapy in Acute Heart Attack. Sherry S. In: “The Myocardium: Failure and Infarction”. Braunwald E. Ed. H. P. Publishing Co.; N. Y.: 317-327 1974
      Google Scholar
    • 24 Altered Coagulability in Tumor Patients. Sherry S. in Paraneoplastic Syndromes. Ed. Hall T. C. N.Y. Academy of Sciences; N. Y.: 1974: 251 294—296.
      Google Scholar
    • 25 Mechanisms of Fibrinolysis. Sherry S. In Hematology. 2nd Edition. Ed. Williams W. J, Beutler E, Erslev A. J, Rundles R. W. Blakiston Division, McGraw-Hill Book Co.; 1976. Chapter 138.
      Google Scholar
    • 26 The Role of the Platelet in Thrombosis. Sherry S. In: “Platelets and Thrombosis”. Mills D. C. B, Pareti F. I. Eds. Academic Press; In press.
      Google Scholar
    • 27 Therapeutic Thrombolysis: Past, Present and Future. In: “Urokinase and Thrombosis”. Paoeletti R, Sherry S. Eds. Academic Press; In press.
      Google Scholar
    • 28 Foreword. Sherry S. In: Heparin, Chemistry and Clinical Use. Kakkar V. V, Thomas D. P. Ed. Academic Press; London: 1976
      Google Scholar
      E.

    • Books and Monographs

    • 1 Thrombosis. Edited by Sherry S, Genton E, Brinkhous K. M, Stengle J. M. National Academy of Sciences; Washington, D. C.: 1969: 762.
      Google Scholar
    • 2 Immunological Mechanisms in Blood Coagulation, Thrombosis and Hemostasis. New Development in Antithrombotic Therapy. Ed: Duckert F, Brinkhous K. M, Hinnom S, Koller F, Sherry S, Stengle J. M. Thrombos. Diathes. haemorrh. (Stuttg.). Suppl. 45. 1971
      PubMedGoogle Scholar
    • 3 The Epidemiology of Venous Thrombosis. Ed: Foster C. S, Genton E, Henderson M, Sherry S, Wessler S. Milbank Memorial Fund Quarterly 10 (01) Part 2: 9-289 1972;
      PubMedGoogle Scholar
    • 4 Thrombosis: Risk Factors and Diagnostic Approaches. Ed: Brinkhous K. M, Owren P. A, Hinnom S, Surgenor D. M, Sherry S, Stengle J. M. Thrombos. Diathes. haemorrh. (Stuttg.) (Suppl. 51) 1972; 1-388.
      PubMedGoogle Scholar
    • 5 The Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Ed: Sasahara A. A, Hyers T, Cole C, Ederer F, Murray J. A, Wenger N. K, Sherry S, Stengle J. M. Circulation 47 Suppl. II 1-108 1973;
      CrossrefPubMedGoogle Scholar
    • 6 Thrombosis: Mechanisms and Control. Ed: Brinkhous K. M, Surgenor D, Hinnom S, Sherry S, Stengle J. M. Thromb. Diathes. haemorrh. (Stuttg.) (Suppl. 54) 1937; 1-464.
      PubMedGoogle Scholar
    • 7 Platelets and Thrombosis. Ed: Sherry S, Scriabine A. University Park Press; Baltimore: 332 1974
      Google Scholar
    • 8 Urokinase and Thrombosis. Ed: Paoletti R, Sherry S. Academic Press; In press.
      Google Scholar
      F.

    • Other Publications

    • 1 Typhus in Lower Bavaria. Sherry S. The Bulletin, U.S. Army Medical Dept 1946; 5: 141.
      PubMedGoogle Scholar
    • 2 The Action of Streptococcal Desoxyribonuclease on Purulent Exudates. Sherry S. Trans. N. Y. Acad. Sc 1952; 14: 138.
      PubMedGoogle Scholar
    • 3 Current Concepts of Diabetes. Sherry S. Bull. N. Y. Acad. of Med 1953; 29: 202.
      PubMedGoogle Scholar
    • 4 Serum Transaminase as a Diagnostic Aid. Chinsky M, Sherry S. A.M.A. Arch. Int. Med 1957; 99: 556.
      CrossrefPubMedGoogle Scholar
    • 5 Biochemical, Experimental and Clinical Studies with Proteolytic Enzymes (with Particular Reference to the Fibrinolytic Enzyme of Human Plasma). Sherry S, Alkjaersig N. Ann. N. Y. Acad of Sciences 1957; 63: 52.
      PubMedGoogle Scholar
    • 6 Studies on the Fibrinolytic Enzyme of Human Plasma. Sherry S, Alkjaersig N. Thrombos. Diathes. haemorrh. (Stuttg.) 1957; 1: 264.
      PubMedGoogle Scholar
    • 7 Possibilities for Therapy with Enzymes. Sherry S. Ann. Otol. (St. Louis) 1959; 68: 34.
      PubMedGoogle Scholar
    • 8 Developments in Fibrinolytic Therapy for Thromboembolic Disease. Sherry S, Fletcher A. P, Alkjaersig N. Ann. intern. Med 1959; 50: 560.
      CrossrefPubMedGoogle Scholar
    • 9 Thrombolytic Therapy for Coronary Heart Disease. Fletcher A. P, Sherry S. Circulation 1960; 22: 619.
      CrossrefPubMedGoogle Scholar
    • 10 Thrombolytic Therapy: Basic and Therapeutic Considerations. Sawyer W. D, Alkjaersig N, Fletcher A. P, Sherry S. Arch. intern. Med 1961; 107: 274.
      CrossrefPubMedGoogle Scholar
    • 11 Hemostatic Mechanisms and Proteolysis in Shock. Sherry S. In Symposium on Shock. Federation Proceedings 1961; 20 (02) Part III (Suppl. 09) 209.
      PubMedGoogle Scholar
    • 12 Thrombolytic Therapy. Sherry S. South Med. J 1961; 54: 1287.
      CrossrefPubMedGoogle Scholar
    • 13 Status of Therapy: Critique and Outlook for the Future. Sherry S. In Thrombolytic Activity and Related Phenomena. Ed. Koller F. Thrombos. Diathes. haemorrh. (Stuttg.) 1962; 6 (Suppl. 01) 344.
      PubMedGoogle Scholar
    • 14 Introduction to Symposium on Thrombosis and Anticoagulation. Sherry S. (Guest Editor) Amer. J. Med 1962; 33: 619.
      CrossrefPubMedGoogle Scholar
    • 15 Fibrinolytic Mechanisms and the Development of Thrombolytic Therapy. Fletcher A. P, Aikjaersig N, Sherry S. Amer. J. Med 1962; 33: 738.
      CrossrefPubMedGoogle Scholar
    • 16 Role of Fibrinolysin Therapy in the Treatment of Acute Myocardial Infarction. Sherry S, Letcher A. P. In Coronary Heart Disease (7th Hahnemann Symposium). Ed. Likoff W, Moyer J. H. Grune & Stratton; N.Y.: 1963: 383.
      Google Scholar
    • 17 Fibrinolytic Bleeding and its Management. Sherry S, Alkjaersig N, Fletcher A. P. Ann. N.Y. Academy of Sciences 1964; 115 (01) 481.
      PubMedGoogle Scholar
    • 18 Fibrinolytic Bleeding and its Control. Sherry S, Fletcher A. P, Alkjaersig N. Annotation. Amer. Heart J 1964; 67: 425.
      PubMedGoogle Scholar
    • 19 Current Status of Thrombolytic Therapy. Sherry S. Geriatrics 1964; 19: 628.
      PubMedGoogle Scholar
    • 20 Fibrinolysis. Sherry S, Fletcher A. P, Alkjaersig N. Physiology for Physicians. 1964 2. No. 4.
      PubMedGoogle Scholar
    • 21 Thromboembolic Disorders. Sherry S, Fletcher A. P, Wessler S. Nat. Conf. Cardiov. Dis 1964; 2: 585.
      PubMedGoogle Scholar
    • 22 Present Concept of the Fibrinolytic System. Sherry S. Series Haematologica, Scand. J. of Haem 1965; 7: 70.
      PubMedGoogle Scholar
    • 23 Current Concepts of the Relationship of Thrombosis and Thrombolysis. Sherry S. Ass. Res. nerv. Dis. Proc 1966; 41: 349.
      PubMedGoogle Scholar
    • 24 Fibrinolysis and Afibrinogenemia. Sherry S. Anaesthesiology 1966; 27: 465.
      CrossrefPubMedGoogle Scholar
    • 25 Perspectives: Fibrinolysis and Thrombolysis. Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; Supplement 20: 1.
      PubMedGoogle Scholar
    • 26 Fibrinolytic Mechanisms in Tissue Injury. Sherry S. Gastroenterology 1966; 51: 901.
      PubMedGoogle Scholar
    • 27 Acute Pulmonary Embolism. Sherry S. Geriatrics 1967; 22: 150.
      PubMedGoogle Scholar
    • 28 Urokinase. Sherry S. Ann. intern. Med 1968; 69: 415.
      CrossrefPubMedGoogle Scholar
    • 29 Fibrinolytic Agents. Sherry S. Disease-a-Month. Year Book Publishers, Inc.; May 1969. Chicago: 1-32.
      Google Scholar
    • 30 Therapeutic Experiences with Urokinase. In Therapeutische and Experimentelle Fibrinolyse. Proceedings of International Symposion. Oct. 1967 in Ulm (Donau). Thrombos. Diathes. haemorrh. (Stuttg.) 1969; Suppl. 32: 373.
      PubMedGoogle Scholar
    • 31 The Kallikrein System: A Basic Defense Mechanism. Sherry S. Hospital Practice 5: 75 1970;
      PubMedGoogle Scholar
    • 32 Current Status of Fibrinogen and Fibrin Degradation Products. Sherry S. Thrombos. Diathes. haemorrh (Stuttg.) 1970; Suppl. 39: 169.
      PubMedGoogle Scholar
    • 33 Reports of Subcommittee on Fibrinolysis and Thrombolysis, International Committee on Haemostasis and Thrombosis. Sherry S. Thrombos. Diathes. haemorrh. (Stuttg) Suppl. 26: 457 1968; Suppl. 35: 181, 1969; Suppl. 39: 453; Suppl. 45: 347, 1971; Suppl. 51, 1972.
      PubMedGoogle Scholar
    • 34 Reaction of Fibrinogen Digests and Purified Fibrinogen Degradation Products in the TRCHII and Staphylococcal Clumping Tests. Application in Clinical Studies. Marder V. J, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 367-372 1971;
      PubMedGoogle Scholar
    • 35 Immunologic Techniques for the Identification of Fibrinogen Derivatives Produced by Enzymatic and Chemical Degradation. Marder V. J, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 269-279 1971;
      PubMedGoogle Scholar
    • 36 The Present Status of Urokinase Trial. Sherry S. for the Urokinase-Pulmonary Embolism Trial Study Group. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 9-21 1971;
      PubMedGoogle Scholar
    • 37 Prospects in Antithrombotic Therapy. Sherry S. Amer. J. Cardiol 29: 81 1972;
      CrossrefPubMedGoogle Scholar
    • 38 Thrombolytic Therapy for Acute Myocardial Infarction. Sherry S. Amer. Heart J 1972; 83: 427-430.
      CrossrefPubMedGoogle Scholar
    • 39 Present Status of Antithrombotic Therapy in Acute Heart Attack. Sherry S. Hospital Practice 7: 45-54 1972;
      PubMedGoogle Scholar
    • 40 Clinical Trials with Antithrombotic and Thrombolytic Agents. Sherry S. Principles and Pitfalls Thrombos Diathes. haemorrh. (Stuttg.) 29: 1-10 1973;
      PubMedGoogle Scholar
    • 41 Trial and Error; Questions and Answers. Sherry S. Transactions of the Plenary Sessions, IV International Congress on Thrombosis and Haemostasis. Ed.: Deutsch E, Lechner K, Brinkhous K, Hinnon S. F. K. Schattauer Verlag; Stuttgart: 263-270 1974
      Google Scholar
    • 42 Coronary Thrombosis in Myocardial Infarction. Chandler A. B, Chapman I, Erbarmt L, Roberts W. C, Schwartz C. J, Sinapius D, Spain D. M, Sherry S, Ness P, Simmon T. L. Amer. J. Cardiol 34: 824-833 1974;
      PubMedGoogle Scholar
    • 43 Urokinase-streptokinase Pulmonary Embolism Trial. (Phase II Results). Bell W, Simon T. L, Stengle J. M, Sherry S. Circulation 50: 1070-1071 1974;
      CrossrefPubMedGoogle Scholar
    • 44 Urokinase in Thrombo-embolic Disease: Pulmonary Embolism. Sasahara A. A, Stengle J. M, Sherry S. Amer. Heart J 89: 403-404 1975;
      CrossrefPubMedGoogle Scholar
    • 45 Diagnostic Developments in Thrombotic Disease. Sherry S. Cardiovascular Diseases Bulletin of the Texas Heart Institute 2: 59-63 1975;
      PubMedGoogle Scholar
    • 46 William Smith Tillett. 1892–1974. Sherry S. Trans. Ass. Amer. Phycns 88: 32-34 1975;
      PubMedGoogle Scholar
    • 47 The Phase II Urokinase-Streptokinase Pulmonary Embolism Trial – A National Cooperative Study. Sasahara A. A, Bell W. R, Simon T. L, Stengle J. M, Sherry S. Thrombos. Diathes. haemorrh. (Stuttg.) 33: 464-476 1975;
      PubMedGoogle Scholar
    • 48 Therapy of Deep Vein Thrombosis and Pulmonary Embolism. Medical Approach. Sherry S. in Prophylactic Therapy of Deep Vein Thrombosis and Pulmonary Embolism. Ed. Fratantoni J, Wessler S. DHEW Publication No (NIH) 76–866 US Department of Health, Education and Welfare; Washington, DC: 127-136 1975
      Google Scholar
    • 49 Prevention of pulmonary embolism with low-dose heparin. Sherry S. Postgrad, med. J 59: 80-84 1976;
      CrossrefPubMedGoogle Scholar
    • 50 Interrelationships between platelets and coagulation in the pathogenesis of venous thrombosis. Sherry S. S. Afr. med. J 50: 425-427 1976;
      PubMedGoogle Scholar
    • 51 Anticoagulant therapy: Questions and answers. Sherry S. Comprehensive Therapy. In press.
      PubMedGoogle Scholar
    • 52 Thrombo-embolism. Sherry S. Proc. Chicago Inst, of Med. In press.
      PubMedGoogle Scholar